Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:6
  • preuzimanja u poslednjih 30 dana:2
članak: 2 od 11  
Back povratak na rezultate
Vojnosanitetski pregled
2020, vol. 77, br. 9, str. 885-892
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 09/10/2020
doi: 10.2298/VSP171226138M
Creative Commons License 4.0
Preživljavanje hirurški lečenih bolesnika sa odmaklim karcinomom larinksa u Srbiji
aKlinički centar Srbije, Klinika za ORL i MFH, Beograd + Univerzitet u Beogradu, Medicinski fakultet, Katedra Otorinolaringologija sa maksilofacijalnom hirurgijom
bGeneral Hospital Loznica, Loznica
cGeneral Hospital "Dr Đorđe Jovanović", Zrenjanin
dUniverzitet u Beogradu, Medicinski fakultet, Institut za farmakologiju, kliničku farmakologiju i toksikologiju
eKlinički centar Srbije, Klinika za fizikalnu medicinu i rehabilitaciju, Beograd
fKlinički centar Srbije, Centar za radiologiju i magnetnu rezonancu, Beograd
gKlinički centar Srbije, Centar za nuklearnu medicinu, Beograd

e-adresa: anajotic@yahoo.com

Sažetak

Uvod/Cilj. Karcinomi larinksa čine 1%-3% svih maligniteta glave i vrata. Terapijski rezultati i preživljavanje umnogome zavise od stadijuma bolesti. Cilj rada bio je da se ispita preživljavanje bolesnika, hirurški lečenih od odmaklih karcinoma larinksa, u zavisnosti od starosti, pola, uobičajenih faktora rizika (pušenje, konzumiranje alkohola), primarne lokalizacije tumora, patohistološkog stadijuma bolesti, tumor, nodus, metastaza (TNM) stadijuma bolesti, i primenjene hirurške terapije bolesti. Metode. Retrospektivnom studijom bilo je obuhvaćeno 252 bolesnika, hirurški lečenih od odmaklih karcinoma glave i vrata, sa periodom praćenja od pet godina. Bolesnici uključeni u studiju primarno su lečeni hirurški, sa sprovođenjem postoperativne radio i hemioterapije, u zavisnosti od lokalne i regionalne proširenosti bolesti, intraoperativnog nalaza i granica linija resekcija. Petogodišnje ukupno preživljavanje i preživljavanje bez znakova bolesti računato je u zavisnosti od demografskih i kliničkih karakteristika bolesnika. Rezultati. Ukupno petogodišnje preživljavanje bolesnika sa odmaklim karcinomima larinksa je iznosilo 86,14%, a petogodišnje preživljavanje bez znakova bolesti 86,51%. Smanjeno preživljavanje bilo je značajno povezano sa starošću bolesnika, višim histološkim gradusom tumora i opsežnijim disekcijama vrata. Zaključak. Primarna totalna laringektomija rezultira dužim preživljavanjem u slučajevima transglotisnih T3 i T4a tumora larinksa. Pre donešenja odluke, bolesnici bi trebali biti informisani o mogućim većim rizicima od smrtnog ishoda povezanim sa izborom hirurške metode i drugih načina lečenja.

Ključne reči

Reference

Novododat članak: provera, normiranje i linkovanje referenci u toku.
Ferlay J ,Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v 1.0,Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 (Internet). France, Lyon: International Agency for Research on Cancer; 2013
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349(22): 2091-8.
Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg 2014; 140(9): 855-60.
Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133(12): 1270-6.
Dziegielewski PT, O'Connell DA, Klein M, Fung C, Singh P, Alex Mlynarek M, et al. Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: a population-based analysis of survival J Otolaryngol Head Neck Surg 2012; 41 Suppl 1: S56-64.
Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardizing survival ratios. Eur J Cancer 2004; 40(15): 2307-16.
National Comprehensive Cancer Network. Head and neck cancers (Version 1.2017). Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. [accessed 2017 September].
Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, et al .Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2017; 7(4): 246-53.
Dyckhoff G, Plinkert PK, Ramroth HA. Change in the study evaluation paradigm reveals that larynx preservation compromises survival in T4 laryngeal cancer patients. BMC Cancer 2017; 17(1): 609.
Brandstorp-Boesen J, Sørum Falk R, Boysen M, Brøndbo K. Impact of stage, management and recurrence on survival rates in laryngeal cancer. PLoS One. 2017; 14; 12(7): e0179371.
Saini AT, Genden EM, Megwalu UC.Sociodemographic disparities in choice of therapy and survival in advanced laryngeal cancer. Am J Otolaryngol 2016; 37(2): 65-9.
de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001; 37(3): 332-9.
Krejović B. The importance of surgery in treatment of malignant laryngeal tumors [dissertation]. Belgrade: Medical Faculty University in Belgrade; 1981. (Serbian)
Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, et al. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324(24): 1685-90.
Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34(3): 224-8.
Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116(9 Pt 2 Suppl 111): 1-13.
Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 2008; 134(4): 370-9.
Francis E, Matar N, Khoueir N, Nassif C, Farah C, Haddad A. T4a laryngeal cancer survival: retrospective institutional analysis and systematic review. Laryngoscope 2014; 124(7): 1618-23.
Olsen KD. Reexamining the treatment of advanced laryngeal cancer. Head Neck 2010; 32(1): 1-7.
Đorđević V, Milovanović J, Petrović Z, Dudvarski Z, Petrović B, Stanković P. Radical surgery of the malignant laryngeal tumors. Acta Chir Iugosl 2004; 51(1): 31-5.
Stanković M, Milisavljević D, Stojanov D, Živić M, Živaljević S, Stanković I, et al, Influential factors, complications and survival rate of primary and salvage total laryngectomy for advanced laryngeal cancer. Coll Antropol 2012; 36(Suppl 2): 7-12.
Ferlito A, Silver CE, Rinaldo A. Selective neck dissection (IIA, III): a rational replacement for complete functional neck dissection in patients with N0 supraglottic and glottic squamous carcinoma. Laryngoscope 2008; 118(4): 676-9.
Suárez C, Rodrigo JP, Robbins KT, Paleri V, Silver CE, Rinaldo A, et al.Superselective neck dissection: rationale, indications, and results. Eur Arch Otorhinolaryngol 2013; 270(11): 2815-21.
Andersen PE, Warren F, Spiro J, Burningham A, Wong R, Wax MK, Shah JP, et al. Results of selective neck dissection in management of the node-positive neck. Arch Otolaryngol Head Neck Surg 2002; 128(10): 1180-4.